p16INK4a Antibody / CDKN2A, 100ug

CDKN2A antibody targets p16INK4a, a cyclin-dependent kinase inhibitor encoded by the CDKN2A gene that functions as a critical tumor suppressor regulating cell cycle progression. p16INK4a inhibits cyclin-dependent kinases CDK4 and CDK6, preventing phosphorylation of the retinoblastoma protein and enforcing G1 phase cell cycle arrest. Through this mechanism, CDKN2A plays a central role in maintaining checkpoint control and limiting uncontrolled cellular proliferation.<br><br>p16INK4a, also referred to as Cyclin-dependent kinase inhibitor 2A in the literature, is a member of the INK4 family of CDK inhibitors and is closely associated with cellular senescence, oncogene-induced stress responses, and aging-related pathways. A CDKN2A antibody recombinant rabbit mAb can be used in studies examining cell cycle regulation, tumor suppressor signaling, and proliferative control. p16INK4a is predominantly localized to the nucleus, although cytoplasmic staining has been reported depending on cell type and biological context.<br><br>Expression of CDKN2A is regulated by multiple mechanisms including epigenetic modification, transcriptional control, and oncogenic signaling cascades. p16INK4a antibody is therefore useful for investigating pathways related to senescence, growth arrest, and checkpoint integrity. Altered p16INK4a expression patterns are commonly examined in research focused on dysregulated proliferation and loss of tumor suppressor function.<br><br>In cancer biology research, CDKN2A is one of the most frequently studied cell cycle regulators due to its involvement in growth suppression and cellular aging. p16INK4a antibody is routinely applied in studies exploring tumor development, cell cycle dysregulation, and mechanisms underlying abnormal checkpoint control. Changes in CDKN2A expression are often evaluated as part of broader investigations into proliferative signaling networks.<br><br>This CDKN2A antibody, clone CDKN2A/13309R, is designed to detect p16INK4a expression in research applications. Recombinant rabbit mAb clone CDKN2A/13309R supports studies of cyclin-dependent kinase inhibition, senescence-associated signaling, and cell cycle regulation involving CDKN2A.

Specifications